← Leaderboards
Stephen R Plymate
University Of Washington
$6,213,858
Attributed
$6,213,858
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,518,403 · 7
VA$0 · 2
By mechanism
U54$4,627,009 · 3
P01$3,487,047 · 3
P50$1,404,347 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Mary L. Disis$210,448,010
- Daniel E Sabath$3,938,304
- Lupe G Salazar$2,699,874
- William G. Carter$3,118,937
- Eva Corey$2,497,094
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorAndrogen ReceptorCastrationProstateMalignant NeoplasmsResistanceTumor ProgressionAffectTumor GrowthSignal TransductionAndrogensReceptor SignalingResponseGenesIn VivoRegulationVariantProgramsReceptor ExpressionIn VitroCancer CellCellsTissues
Grant awards (41)
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer$0
I01 · FY2024 · VA · contact PI
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer$0
I01 · FY2023 · VA · contact PI
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer$0
I01 · FY2022 · VA · contact PI
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer$0
I01 · FY2021 · VA · contact PI
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate Cancer$0
I01 · FY2020 · VA · contact PI
Approach to the Aberrant Androgen Receptor Signaling in Lethal Prostate Cancer$0
I01 · FY2019 · VA · contact PI
Approach to the Aberrant Androgen Receptor Signaling in Lethal Prostate Cancer$0
I01 · FY2018 · VA · contact PI
Development of Castration Resistance by Alternative AR Splicing$389,164
P01 · FY2017 · CA · contact PI
Approach to the Aberrant Androgen Receptor Signaling in Lethal Prostate Cancer$0
I01 · FY2017 · VA · contact PI
Development of Castration Resistance by Alternative AR Splicing$389,080
P01 · FY2016 · CA · contact PI
Approach to the Aberrant Androgen Receptor Signaling in Lethal Prostate Cancer$0
I01 · FY2016 · VA · contact PI
Development of Castration Resistance by Alternative AR Splicing$411,155
P01 · FY2015 · CA · contact PI
Development of Castration Resistance by Alternative AR Splicing$376,724
P01 · FY2014 · CA · contact PI
Development of Castration Resistance by Alternative AR Splicing$406,540
P01 · FY2013 · CA · contact PI
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost$279,177
P01 · FY2013 · CA · contact PI
Mechanisms for the Transition to Castrate Resistant Prostate Cancer$0
I01 · FY2013 · VA · contact PI
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost$303,519
P01 · FY2012 · CA · contact PI
Mechanisms for the Transition to Castrate Resistant Prostate Cancer$0
I01 · FY2012 · VA · contact PI
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost$304,747
P01 · FY2011 · CA · contact PI
P-4: Mechanisms by Which the T1 Insulin-like Growth Factor Inhibition Enhances$278,052
P50 · FY2011 · CA · contact PI
Mechanisms for the Transition to Castrate Resistant Prostate Cancer$0
I01 · FY2011 · VA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$560,098
U54 · FY2010 · CA · contact PI
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost$313,602
P01 · FY2010 · CA · contact PI
P-4: Mechanisms by Which the T1 Insulin-like Growth Factor Inhibition Enhances$291,489
P50 · FY2010 · CA · contact PI
Laminin Dysregulation and Prostate Cancer$232,066
U54 · FY2010 · CA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$913,934
U54 · FY2009 · CA · contact PI
Laminin Dysregulation and Prostate Cancer$382,198
U54 · FY2009 · CA · contact PI
Determinants of Response to Type 1 Insulin-Like Growth Factor Inhibition in Prost$313,339
P01 · FY2009 · CA · contact PI
Mechanisms by Which the Type 1 Insulin-like Growth Factor Inhibition Enhances$291,197
P50 · FY2009 · CA · contact PI
Mechanisms for the Transition to Castrate Resistant Prostate Cancer$0
I01 · FY2009 · VA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$617,704
U54 · FY2008 · CA · contact PI
Mechanisms by Which the Type 1 Insulin-like Growth Factor Inhibition Enhances$287,070
P50 · FY2008 · CA · contact PI
Laminin Dysregulation and Prostate Cancer$257,613
U54 · FY2008 · CA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$558,209
U54 · FY2007 · CA · contact PI
Mechanisms by Which the Type 1 Insulin-like Growth Factor Inhibition Enhances$256,539
P50 · FY2007 · CA · contact PI
Laminin Dysregulation and Prostate Cancer$243,351
U54 · FY2007 · CA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$54,600
U54 · FY2007 · CA · contact PI
Significance of Microenvironment for Prostate Cancer Initiation and Progression$600,000
U54 · FY2006 · CA · contact PI
Laminin Dysregulation and Prostate Cancer$164,803
U54 · FY2006 · CA · contact PI
Administration and Data Management Core$42,433
U54 · FY2006 · CA · contact PI
ANDROGEN INDEPENDENT METASTATIC DISEASE$0
P01 · FY2002 · CA